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Clinicians have traditionally used clinicopathological (CP) factors to determine locoregional recurrence (LR) risk of breast
cancer and have generated the IBTR! nomogram to predict the risk of ipsilateral breast tumor recurrence (IBTR). The
21-gene recurrence score (RS) assay was recently correlated with LR in retrospective studies. The objective of this
study was to examine the relationship between the RS and IBTR!. CP characteristics of 308 consecutive patients who
underwent RS testing at our institution were examined. IBTR! was used to estimate the risk of 10-year IBTR. Descriptive
statistics were used to compare the RS with the estimated IBTR!. Given a low event rate in this cohort, actual IBTR rates
were not reported. Most patients had stage I/II (98%) and grade I/II (77%) disease. Median age was 54 years (range,
30–78). Median IBTR! without radiation therapy was 10% (mean, 12% [range, 4-43%]). RS was low (<18), intermediate
(18–30), and high (>30) in 52% (n = 160), 40% (n = 123), and 8% (n = 25) patients. Overall, IBTR! did not correlate with
RS (P = .77). We saw no correlation between RS and IBTR! in patients with less than (P = .32) or greater than (P = .48) a
10% risk of IBTR. Interestingly, Ki-67 expression correlated with both IBTR! (P = .019) and the RS (P = .002). Further study
is warranted to determine if the RS can provide complementary biological information to CP factors in estimating the
risk of LR. Prospective studies evaluating this association may potentially allow for individualized treatment decisions.
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Local recurrenceIntroduction
Local treatment decisions for patients with breast cancer
are traditionally based on conventional clinicopatholo-
gical (CP) factors such as age, tumor size and grade,
TNM stage, margin status, lymphovascular invasion
(LVSI), chemotherapy use, and hormone therapy use. A
web-based predictive nomogram IBTR! (IBTR Version 2
0 Breast Cancer Model) is commonly used to estimate a
patient’s risk of ipsilateral breast tumor recurrence
(IBTR) according to several well-established CP factors
(Sanghani et al. 2007; Sanghani et al. 2010). However,* Correspondence: wwoodward@mdanderson.org
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in any medium, provided the original work is pbreast cancer is actually a heterogeneous group of dis-
eases, and definitive treatment options may vary by mo-
lecular subtype.
Physicians have incorporated several molecular pro-
filing tools into breast cancer clinics (Paik et al. 2004;
Goldstein et al. 2008; Tang et al. 2011). The most widely
used gene expression profiling tool is the 21-gene Onco-
type Dx Recurrence Score (RS) assay (OncotypeDX;
GenomicHealth Inc., Redwood City, Calif.), which is
used to estimate the risk of 10-year distant recurrence
(DR) and predict the likelihood of benefit of adjuvant
chemotherapy for hormone receptor (HR)-positive,
node-negative, tamoxifen-treated breast cancer (Paik
et al. 2004; Paik et al. 2006). Both the National Com-
prehensive Cancer Network and American Society ofn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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option for evaluating early-stage, HR-positive, lymph
node-negative breast cancer (Network 2013; Harris et al.
2007).
Despite rapid integration of these genetic tools to as-
sess the need for systemic management of breast cancer,
their use in estimating the risk of locoregional recur-
rence (LR), which includes IBTR, chest wall recurrence,
and regional nodal recurrence, has remained under-
developed. Recent studies suggest that molecular pro-
filing tools designed to assess the risk of DR, such as the
RS, also predict increased risk of LR (Haffty 2002; Voduc
et al. 2010; Mamounas et al. 2010; Taghian et al. 2004;
Wapnir et al. 2008; Kirk 2010; Cheng et al. 2006; Nuyten
et al. 2006). However, detailed information about the
overlap between molecular-based risk stratification and
standard CP factors that are known causes of LR is
unavailable. Elucidation of this relationship would be
useful, because clinicians have traditionally utilized CP
factors to predict the risk of IBTR, and molecular tools
hold the future promise for predicting the risk of LR.
The objective of the present study was to examine the
relationship between the 21-gene RS and the estimated
risk of IBTR based on CP features in breast cancer pa-
tients primarily at intermediate-risk for IBTR, for whom
clinical uncertainty exists as to the need for therapeutic
escalation versus de-escalation. We sought to identify
clinical scenarios in which the RS may complement CP




Patients diagnosed with breast cancer who underwent
the 21-gene RS assay testing as part of routine care or in
the context of the National Cancer Institute’s Trial Assign-
ing IndividuaLized Options for Treatment (TAILORx)
trial from December 2004 to November 2008 were in-
cluded in this study. In the TAILORx trial, researchers are
evaluating whether hormone therapy alone or with
combination chemotherapy is better for women with
node-negative, estrogen receptor (ER)-positive breast
cancer having an RS of 11–25 (Hormone Therapy With or
Without Combination Chemotherapy in Treating Women
Who Have Undergone Surgery for Node-Negative Breast
Cancer (The TAILORx Trial) 2013). Patients who were
clinically node-negative but pathologically node-positive
during this time period were also included in this cohort
as part of routine care at this institution.
Demographic and CP data on the study patients were
abstracted from a prospectively maintained clinical data-
base according to an MD Anderson Institutional Review
Board-approved protocol. All pathological information,
including histological type, tumor grade, tumor size,nodal status, and tumor marker expression were re-
viewed by breast pathologists. Ki-67 expression was
measured using immunohistochemistry as part of the
routine pathological evaluation and was reported as the
percentage of Ki-67 positive nuclei in invasive neoplastic
cells. Ki-67 expression information was available for 116
of 308 patients.
The 21-gene RS
Tumor samples obtained from the study patients were
submitted for the 21-gene RS assay (OncotypeDX; Gen-
omicHealth Inc., Redwood City, Calif.). This profiling
tool measures the expression of 16 cancer-related and 5
control genes in paraffin-embedded breast tumor sam-
ples using a reverse transcriptase-polymerase chain reac-
tion assay as described previously (Paik et al. 2004).
Based on the level of expression of each gene, a conti-
nuous variable known as the RS is calculated, ranging
from 0 to 100. This score can be used to estimate the
risk of 10-year DR and predict the likelihood of adjuvant
chemotherapy benefit in patients with node-negative,
HR-positive, tamoxifen-treated breast cancer (Paik et al.
2004; Paik et al. 2006).
IBTR! nomogram
The IBTR! nomogram (version 2.0; Breast Cancer Model)
is a web-based predictive tool that uses literature-derived
relative risk ratios for seven CP tumor factors (age, tumor
size and grade, margin status, LVSI, and chemotherapy
and hormone therapy use) to predict the 10-year risk of
IBTR with and without radiation therapy (RT) (Sanghani
et al. 2010). The 10-year estimated risk of IBTR was calcu-
lated and recorded for each patient using IBTR! (IBTR
Version 2 0 Breast Cancer Model; Sanghani et al. 2010).
IBTR! without RT was used in this study (Sanghani et al.
2010).
Statistical analysis
Descriptive statistics were used to compare the RS with
the estimated 10-year risk of IBTR!. Analysis of variance
with Tukey’s adjustment for multiple comparisons was
used to compare scores among various factors. Correla-
tions among RS, age, and Ki-67 expression were also
evaluated. Spearman’s rank correlation coefficient was
used to estimate the strength of association between RS
and IBTR!, RS and Ki-67 expression, IBTR! and Ki-67
expression, and IBTR! and age at diagnosis. Ki-67 was
compared as a categorical variable and as a continuous
variable. Stratification according to type of local treat-
ment was also include for the IBTR! and RS compari-
sons. All significance tests were two-tailed, with P values
less than .05 considered significant. Analyses were per-
formed using the SAS software program (version 9.3 for
Windows; SAS Institute Inc., Cary, N.C.). Actuarial LR,
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a short median follow-up duration and low event rate.
Results
Patient and tumor characteristics
We identified 308 consecutive patients who underwent
the RS assay (Table 1). Their median age was 54 years
(range, 30–78 years). Ninety-nine percent of patients
(N = 305) had stage I/II disease, and 77% (N = 238) had
grade I/II tumors. Sixty-six percent (N = 203) underwent
breast-conserving surgery (BCS; 6% [N = 19] alone and
60% [N = 184] with RT), and 34% (N = 105) underwent
mastectomy (31% [N = 96] alone and 3% [N = 9] with
RT). We classified 52% (N = 160), 40% (N = 123), and
8% (N = 25) of the patients into the low-risk (<18),
intermediate-risk (18–30), and high-risk (>30) cate-
gories as defined by the assay. Using the TAILORx risk
groups, we classified 69% (N = 212) of the patients into
the intermediate-risk group (RS of 11–25).
Correlation of CP factors with 21-gene RS
High (>20%) Ki-67 expression (Delpech et al. 2012;
Kilickap et al. 2014), high tumor grade, LVSI, and che-
motherapy use was seen in a greater proportion of the
high RS group than in the low and intermediate RS
groups. However, we saw no differences in pathological
stage, type of surgery (BCS versus mastectomy), number
of positive lymph nodes, or tumor size among the risk
groups (Table 1). When we stratified the CP factors by
type of surgery (BCS versus mastectomy), we observed
no significant differences according to RS risk group,
tumor grade, LVSI, or chemotherapy use. However, pa-
tients who underwent mastectomy tended to have larger
primary tumors (P = .0069) and more hormone therapy
use (P = .0406) than did patients who underwent BCS.
Correlation of IBTR! score and RS
The median IBTR! score in all 308 patients was 10%
(mean, 12% [range, 4-43%]). As expected, young age
(P < .001) and high tumor grade associated most strongly
with higher IBTR! scores (Figure 1) (P < .001). Interes-
tingly, Ki-67 expression correlated with both IBTR! and
RS (Figure 2A, B). However, IBTR! score did not cor-
relate with RS (P = .7655, r = .017) (Figure 3A). Among
patients with less than a 10% risk of IBTR (n = 132), 50%
had low RSs, whereas the remaining 50% had intermedi-
ate or high RSs (Figure 3B). Likewise, we did not observe
significant correlation of IBTR! score with RS at higher
IBTR! scores (Figure 3C). Additionally, there was no sig-
nificant difference in the distribution of RS when IBTR
was low (<10%) or high (>10%) (Figure 3D). Stratifica-
tion of IBTR! scores according to TAILORx risk groups
(RS < =25 and RS > 25) further emphasized the widevariation in IBTR! score with either a high or low to
intermediate RS and no correlation (Figure 3E).
We then estimated the IBTR! scores for each of the
four treatment groups, based upon the actual treatments
received (BCS, breast conserving therapy [BCT], Mast-
ectomy, and Mastectomy and postoperative radiation
therapy [PORT]). Previous comparisons utilized the
IBTR! without RT for all patients to provide a more
homogeneous IBTR! score estimate. These comparisons
once again confirmed that patients at high or low risk
for IBTR! based on CP factors and treatment (Figure 4A)
still had large variations in RS (Figure 4B), emphasizing
the need to evaluate molecular profiles in homoge-
neously treated populations of breast cancer patients.
The distribution in BCS and mastectomy subgroups are
wide in both the IBTR! and RS stratifications. However,
the deviation is less in the groups that have undergone RT.
Discussion
Physicians have traditionally based LR treatment deci-
sions for patients with early-stage breast cancer on CP
characteristics such as tumor size and grade, margin sta-
tus, pathological nodal status, and LVSI. However, breast
cancer represents a heterogeneous group of diseases,
and additional biological information about tumor gene
expression may assist in local therapy decisions. Despite
major progress in identifying genomic profiles associated
with risk of DR and benefit of chemotherapy, only re-
cently have studies demonstrated that the 21-gene RS
may help estimate the risk of LR (Voduc et al. 2010;
Mamounas et al. 2010). To date, though, researchers
have yet to explicitly determine how many patients with
seemingly innocuous breast cancer in terms of LR esti-
mates may have high RSs or vice versa. The present
study demonstrated minimal redundancy between CP
risk factors and RS, suggesting that the 21-gene RS adds
complementary biological information to the CP factors
traditionally used to assess risk of IBTR.
Several promising studies recently examined the rela-
tionship between the RS and LR (Table 2). Mamounas
et al. (Mamounas et al. 2010) initially examined the cor-
relation between the 21-gene RS and LR risk in patients
with node-negative, ER-positive breast cancer treated with
breast conservation therapy (BCT) or mastectomy with-
out RT. The authors concluded that RS was highly asso-
ciated with risk of LR in patients with tamoxifen-treated,
placebo-treated, or chemotherapy- plus tamoxifen-treated
disease. RS, age, and initial treatment type were indepen-
dent predictors of LR. However, the relationship was more
complex in patients who received RT, suggesting that the
effectiveness of RT increases as the RS increases. Solin
et al. reported more conflicting results (Solin et al. 2012).
They demonstrated that neither biological subtype nor
21-gene RS were associated with LR, although RS was a
Table 1 Patient demographics and characteristics










Median age at diagnosis, y (range) 54 (30–78) 53 (31–78) 55 (30–73) 59 (40–75) NS
Frequency by race NS
Asian/Pacific Islander 10 (3) 7 (4) 2 (2) 1 (4)
Black 16 (5) 7 (4) 7 (6) 2 (8)
Native American 1 (0.3) 1 (1) 0 (0) 0 (0)
Other 2 (1) 0 (0) 1 (1) 1 (4)
Spanish/Hispanic 42 (14) 24 (15) 14 (11) 4 (16)
White 237 (77) 121 (76) 99 (81) 17 (68)
Type of surgery NS
BCT 203 (66) 100 (63) 85 (69) 18 (72)
Mastectomy 105 (34) 60 (38) 38 (31) 7 (28)
Histology .0225
Invasive ductal 214 (70) 100 (63) 91 (74) 23 (92)
Invasive lobular 37 (12) 24 (15) 13 (11) 0 (0)
Other 57 (19) 36 (23) 19 (15) 2 (8)
Pathological stage NS
0 3 (1) 3 (2) 0 (0) 0 (0)
I 243 (79) 127 (79) 97 (79) 19 (76)
IIA 52 (17) 25 (16) 21 (17) 6 (24)
IIB 7 (2) 3 (2) 4 (3) 0 (0)
IIIA 1 (0.3) 1 (1) 0 (0) 0 (0)
IIIB 1 (0.3) 1 (1) 0 (0) 0 (0)
No. of positive lymph nodes NS
0 286 (93) 152 (95) 110 (89) 24 (96)
1 15 (5) 4 (3) 10 (8) 1 (4)
2 2 (1) 0 (0) 2 (2) 0 (0)
3 1 (0.3) 1 (1) 0 (0) 0 (0)
4 1 (0.3) 1 (1) 0 (0) 0 (0)
Tumor grade <.0001
I 45 (15) 31 (19) 14 (11) 0 (0)
II 193 (63) 107 (67) 80 (65) 6 (24)
III 70 (23) 22 (14) 29 (24) 19 (76)
PR status <.0001
Positive 272 (88) 145 (91) 112 (91) 15 (60)
Negative 31 (10) 10 (6) 11 (89) 10 (40)
Unknown 5 (2) 5 (3) 0 (0) 0 (0)
Ki-67 expression .0024
High (>20%) 27 (9) 9 (6) 11 (9) 7 (28)
Intermediate (10-20%) 41 (13) 23 (14) 16 (13) 2 (8)
Low (<10%) 48 (16) 29 (18) 19 (16) 0 (0)
Not measured 195 (63) 99 (62) 77 (63) 16 (64)
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Vascular invasion .0162
Positive 41 (13) 16 (10) 17 (14) 8 (32)
Negative 267 (87) 144 (90) 106 (86) 17 (68)
Tumor size NS
<2 cm 230 (75) 119 (75) 93 (76) 18 (72)
≥2 cm 73 (24) 38 (24) 28 (23) 7 (28)
Chemotherapy use <.0001
Yes 81 (26) 15 (9) 47 (38) 19 (76)
No 227 (74) 145 (91) 76 (62) 6 (24)
Hormone therapy use .0220
Yes 264 (86) 145 (91) 100 (81) 19 (76)
No 44 (15) 15 (9) 23 (19) 6 (24)
Abbreviations: BCT breast conserving therapy, NS not significant, PR progesterone receptor.
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with HR-positive tumors. The authors concluded that nei-
ther biological subtype nor 21-gene RS should preclude
BCT with RT.
More recently, several groups examined the prog-
nostic and predictive ability of the 21-gene RS assay in
other subgroups of breast cancer patients. For example,
Mamounas et al. (Mamounas et al. 2013) reported a sig-
nificant association between RS and LR after BCT or
mastectomy in patients with at least four positive nodes
and a nonsignificant trend in patients with one to three
positive nodes. Solin et al. (Solin et al. 2013) modified
the 21-gene RS assay to create a ductal carcinoma in situ
(DCIS) RS, incorporating expression data on seven
cancer-related genes and five reference genes. They
found that the continuous DCIS RS was significantly as-
sociated with the risk of an ipsilateral breast event after
BCS without RT. Nevertheless, the possibility that these
tools are useful to identify patients not typically offered
RT who are at higher risk than their CP factors estimate
or to identify patients typically offered RT who may be
safely observed is appealing. Prospective trials will be
needed to confirm how RS segregates from clusters of
standard CP factors.
While researchers have examined the correlations
among CP factors and RSs, they have yet to report data
assessing the range of scores within each subgroup that
would typically be considered indicative of low or high
risk of LR. From a chemotherapy perspective, 40% of the
patients in our cohort had intermediate RSs ranging
from 18 to 30; this group expanded to 69% with the use
of TAILORx risk grouping, reflecting the high propor-
tion of intermediate-risk clinical scenarios. Given the
overlap between IBTR risk estimates based on CP fac-
tors and RS, our cohort also represents a clinically am-
biguous group from an LR standpoint. Although IBTR!score did not correlate with RS in our study, the large
variations in RS and IBTR! score suggest that these
factors provide different information regarding the risk
of IBTR. Interestingly, Ki-67 expression correlated with
both RS and IBTR! score. Although Ki-67 expression is
part of the RS calculation, it is not part of the IBTR!
score calculation. This implies that cellular proliferation
may represent a genetic driver of LR.
The present study demonstrates that breast cancer pa-
tients who are typically offered the 21-gene RS testing
are clinically, pathologically, and perhaps molecularly
heterogeneous. We included patients given treatment
with various modalities, including BCS, BCT, mas-
tectomy alone, and mastectomy with PORT. As further
research is conducted, evaluating the risk of LR in
homogeneously treated populations will be important, as
the risk factors driving relapse after BCS or mastectomy
may be different from those after BCT or PMRT. Neo-
adjuvant systemic therapy is yet another consideration
when evaluating the molecular drivers of LR. Addition-
ally, although researchers have suggested that LR and
DR are linked, CP factors and molecular profiles asso-
ciated with LR may differ from those that predict DR.
For instance, Solin et al. (Solin et al. 2013) modified the
constituent gene profile for the DCIS RS to better re-
flect known biological differences between invasive and
in situ disease. More comprehensive genetic analyses
may define additional or alternative genes that better
predict LR than does the 21-gene RS assay used in this
study.
Although exploratory in nature, our study has several
limitations, including those inherent to retrospective
studies. IBTR risk estimation using IBTR! is intended for
the breast-conserved population, but we applied this
analysis to patients who underwent either breast con-
serving surgery (BCS) or mastectomy. However, our
Figure 1 IBTR! score according to patient and tumor characteristics. (A) IBTR! stratified according to age, tumor size, surgery type, tumor
grade, RS risk group, and Ki-67 expression. (B) IBTR! according to age at diagnosis.
Figure 2 Correlation of Ki-67 expression with (A) IBTR! score and (B) RS.
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Figure 3 Comparisons of the IBTR! score according to the 21-gene RS. (A) The 21-gene RS versus estimated IBTR! score according to CP
factors. (B and C) The 21-gene RS versus IBTR! when the IBTR! was (B) less than 10% and (C) greater than 10%. (D) The frequency distribution of
IBTR! score according to 21-gene RS. (E) Scatter plot of the large variations in IBTR! in the TAILORx risk groups.
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tors rather than the actual treatment received. The overall
non-significant differences between the two treatment co-
horts also suggests that we could indeed isolate and com-
pare IBTR! based upon the CP factors alone. Furthermore,
researchers have suggested that IBTR! overestimates theFigure 4 IBTR! and the 21-gene RS according to actual treatments rec
(B) RS according to actual treatment (i.e., adjuvant RT). The distribution in B
stratifications. However, the deviation is less in the groups that have under
therapy; PORT, post-operative radiation therapy.risk of IBTR in high-risk patients. We also could not ac-
count for factors other than those used in the IBTR! nomo-
gram, as we did not examine actuarial event rate data.
Importantly, IBTR! does not incorporate hormone receptor
or HER2 status, and recent studies have suggested that re-
ceptor status can influence IBTR (Arvold et al. 2011).eived. (A) IBTR! score according to actual treatment (i.e., adjuvant RT).
CS and mastectomy subgroups are wide in both the IBTR! and RS
gone RT. BCS, breast conservation surgery; BCT, breast conservation
Table 2 Summary of studies assessing the relationship of the RS and LR in breast cancer
Study Molecular
profiling tool
Population Objective Number of patients in
the study
Outcomes and conclusions
Thaker et al. (present study) 21-gene RS assay Early-stage, HR-positive, lymph
node-negative
Correlation between
21-gene RS and IBTR!
nomogram
308 No correlation between 21-gene
RS and IBTR! estimates; RS may
complement traditional CP factors
when assessing risk of IBTR in
intermediate-risk patients
Mamounas et al. 21-gene RS assay Tamoxifen-treated, node-negative,
ER-positive disease treated with
placebo, tamoxifen, or chemotherapy
plus tamoxifen from two NSABP trials
(B-14 and B-20)
Association between RS





Significant association between RS
and risk for LR; LR was significantly
associated with RS risk group in
tamoxifen-treated, placebo-treated,
and chemotherapy- plus
tamoxifen-treated patients; RS was
an independent significant predictor
of LR along with age and type of initial
treatment
Solin et al. 21-gene RS assay Operable breast adenocarcinoma
with either 1–3 axillary lymph nodes
involved or negative axillary lymph
nodes with a primary tumor size >1 cm;
patients with HR-positive tumors received
adjuvant hormonal therapy; patients




21-gene RS and biological
subtype relative to LR
after BCT
388 Neither biological subtype nor 21-gene
RS was associated with LR; for HR-positive
tumors, the 21-gene RS evaluated as a
continuous variable was significant for LR;
neither biological subtype nor 21-gene RS
should preclude BCT with RT
Mamounas et al. 21-gene RS assay ER-positive, tamoxifen-treated,
node-positive disease treated
with adjuvant chemotherapy with
AC versus AC-T in the NSABP
B-28 trial
Association between RS
and risk of LR
1065 RS was significantly associated with LR
after lumpectomy and breast RT and
after mastectomy (no RT) as well as in
patients with ≥4 positive nodes (with a
nonsignificant trend in patients with 1–3
positive nodes); in MVA, RS, nodal status,
and tumor size were all independent
predictors of LR
Solin et al. DCIS RS assay DCIS treated with surgical excision
without RT in the ECOG E5194 study
Association of DCIS score
(modified RS assay with 7
cancer-related genes and
5 reference genes) with
risk of IBE
327 Continuous DCIS score was significantly
associated with the risk of an IBE and
invasive IBE; this score complements
traditional CP factors
Abbreviations: NSABP National Surgical Adjuvant Breast and Bowel Project, AC doxorubicin plus cyclophosphamide, AT doxorubicin plus docetaxel, ECOG Eastern Cooperative Oncology Group, AC-T AC followed by
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timate of the risk of IBTR at 10-years, so continuous risk
estimates before and after 10-years were not evaluable.
Furthermore, our cohort comprised an overall favorable
group of patients with node-negative disease. Consistent
with previously published studies, (Paik et al. 2004;
Mamounas et al. 2010; Solin et al. 2012; Mamounas
et al. 2013) the actuarial event rates in such patients are
low, requiring large patient cohorts with long follow-up
durations for examination of actual outcomes. Accor-
ding to these data, we hypothesize that RSs may vary
similarly in patients with node-positive breast cancer, for
whom the decision to add a supraclavicular field to BCT
or give postmastectomy radiation therapy (PMRT) may
be most influenced by the addition of an independent
factor that correlates with LR. However, our cohort did
not have node-positive disease, and this relationship re-
mains to be explicitly shown.
Despite these drawbacks, molecular profiling for LR
continues to rapidly evolve. RS groups and their risks
of IBTR are largely heterogeneous, and discordant RS
values may provide information beyond that provided by
standard CP factors. Indeed, integrating the RS with
traditional CP parameters, treatment type, and patient-
related factors may improve estimation of the risk of LR
over use of any of these factors alone. Goldstein et al.
and Tang et al. reported that combining the RS with
traditional CP factors can improve prognosis for DR,
(Goldstein et al. 2008; Tang et al. 2011) and such a cli-
nical integrator may be an important new tool for
estimating LR risk. The PAM-50 assay (Nanostring Pro-
signa assay) integrates clinical and molecular prognostic
models to estimate the risk of later recurrence in post-
menopasual, HR-positive breast cancer patients and is
now commercially available. Future research efforts will
require prospective assessment of these factors in large
data sets to confirm, validate, and even integrate mo-
lecular signatures with CP factors in intermediate-risk
patients. These data will help establish the number of
patients with intermediate- and high-RS in low-risk sub-
groups required to screen in clinical trials, ultimately
leading to personalization of treatment and improved
outcomes.
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